临床药理学 = 疾病进展 + 药物作用。
Clinical pharmacology = disease progression + drug action.
作者信息
Holford Nick
机构信息
Department of Pharmacology & Clinical Pharmacology, University of Auckland, Auckland, New Zealand.
出版信息
Br J Clin Pharmacol. 2015 Jan;79(1):18-27. doi: 10.1111/bcp.12170.
Abstract
Clinical pharmacology is concerned with understanding how to use medicines to treat disease. Pharmacokinetics and pharmacodynamics have provided powerful methodologies for describing the time course of concentration and effect in individuals and in populations. This population approach may also be applied to describing the progression of disease and the action of drugs to change disease progress. Quantitative models for symptomatic and disease-modifying effects of drugs are valuable not only for describing drugs and diseases but also for identifying criteria to distinguish between types of drug actions, with implications for regulatory decisions and long-term patient care.
摘要
临床药理学关注的是如何使用药物来治疗疾病。药代动力学和药效学为描述个体及群体中药物浓度和效应的时间过程提供了强大的方法。这种群体方法也可用于描述疾病的进展以及药物改变疾病进程的作用。药物对症和疾病修饰作用的定量模型不仅对于描述药物和疾病很有价值，而且对于确定区分不同类型药物作用的标准也很有价值，这对监管决策和长期患者护理具有重要意义。
相似文献
1
Clinical pharmacology = disease progression + drug action.临床药理学 = 疾病进展 + 药物作用。
Br J Clin Pharmacol. 2015 Jan;79(1):18-27. doi: 10.1111/bcp.12170.
2
Systems pharmacology - Towards the modeling of network interactions.系统药理学——迈向网络相互作用建模
Eur J Pharm Sci. 2016 Oct 30;94:4-14. doi: 10.1016/j.ejps.2016.04.027. Epub 2016 Apr 27.
4
Progress in the search for ideal drugs.寻找理想药物的进展。
Pharmacology. 2002 Jan;64(1):1-7. doi: 10.1159/000056144.
5
Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology.基于生理药代动力学模型的模拟应用于监管决策及其对美国处方信息的影响：美国 FDA 临床药理学办公室 2018-2019 年提交文件的更新。
J Clin Pharmacol. 2020 Oct;60 Suppl 1:S160-S178. doi: 10.1002/jcph.1767.
6
Using disease progression models as a tool to detect drug effect.使用疾病进展模型作为检测药物效果的工具。
Clin Pharmacol Ther. 2007 Jul;82(1):81-6. doi: 10.1038/sj.clpt.6100228. Epub 2007 May 16.
7
Introduction of quantitative methods in pharmacology and clinical pharmacology: a historical overview.药理学与临床药理学中定量方法的引入：历史概述
Clin Pharmacol Ther. 2007 Jul;82(1):3-6. doi: 10.1038/sj.clpt.6100248.
8
A Perspective on Quantitative Systems Pharmacology Applications to Clinical Drug Development.定量系统药理学在临床药物研发中的应用展望
CPT Pharmacometrics Syst Pharmacol. 2020 Dec;9(12):675-677. doi: 10.1002/psp4.12567. Epub 2020 Nov 7.
9
The integration of pharmacokinetics and pharmacodynamics: understanding dose-response.药代动力学与药效学的整合：理解剂量反应。
Annu Rev Pharmacol Toxicol. 2004;44:111-36. doi: 10.1146/annurev.pharmtox.44.101802.121347.
10
Trial treatment length optimization with an emphasis on disease progression studies.以疾病进展研究为重点的试验治疗时长优化。
J Clin Pharmacol. 2009 Mar;49(3):323-35. doi: 10.1177/0091270008329560.
引用本文的文献
1
Pharmacometric modeling of drug adverse effects: an application of mixture models in schizophrenia spectrum disorder patients treated with clozapine.药物不良反应的药物代谢动力学建模：混合模型在氯氮平治疗精神分裂症谱系障碍患者中的应用。
J Pharmacokinet Pharmacodyn. 2023 Feb;50(1):21-31. doi: 10.1007/s10928-022-09833-9. Epub 2022 Nov 15.
2
Dose/exposure-response modeling in dose titration trials: Overcoming the titration paradox.剂量/暴露-反应建模在剂量滴定试验中：克服滴定悖论。
CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1592-1603. doi: 10.1002/psp4.12863. Epub 2022 Sep 20.
3
Improving categorical endpoint longitudinal exposure-response modeling through the joint modeling with a related endpoint.通过与相关终点联合建模来改进分类终点纵向暴露-反应建模。
J Pharmacokinet Pharmacodyn. 2022 Jun;49(3):283-291. doi: 10.1007/s10928-021-09796-3. Epub 2021 Nov 20.
4
Applying Beta Distribution in Analyzing Bounded Outcome Score Data.应用 Beta 分布分析有界结局评分数据。
AAPS J. 2020 Mar 17;22(3):61. doi: 10.1208/s12248-020-00441-4.
5
Liver Microphysiological Systems for Predicting and Evaluating Drug Effects.用于预测和评估药物作用的肝脏微生理系统。
Clin Pharmacol Ther. 2019 Jul;106(1):139-147. doi: 10.1002/cpt.1458. Epub 2019 Jun 4.
6
Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models.基于非线性混合效应模型的剂量发现试验中模型平均法与模型选择法的比较。
AAPS J. 2018 Mar 29;20(3):56. doi: 10.1208/s12248-018-0205-x.
7
The pharmaceutical industry needs more clinical pharmacologists.制药行业需要更多的临床药理学家。
Br J Clin Pharmacol. 2017 Nov;83(11):2343-2346. doi: 10.1111/bcp.13370. Epub 2017 Aug 16.
8
Modeling Disease Progression: Angiotensin II Indirectly Inhibits Nitric Oxide Production via ADMA Accumulation in Spontaneously Hypertensive Rats.疾病进展建模：在自发性高血压大鼠中，血管紧张素II通过不对称二甲基精氨酸（ADMA）的积累间接抑制一氧化氮生成。
Front Physiol. 2016 Nov 17;7:555. doi: 10.3389/fphys.2016.00555. eCollection 2016.
9
Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium.中度至重度HIV相关神经认知障碍：锂盐的一项随机安慰剂对照试验。
Medicine (Baltimore). 2016 Nov;95(46):e5401. doi: 10.1097/MD.0000000000005401.
10
Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.疾病状态下药物作用的动力学：迈向基于生理学的药效学（PBPD）模型。
J Pharmacokinet Pharmacodyn. 2015 Oct;42(5):447-62. doi: 10.1007/s10928-015-9437-x. Epub 2015 Aug 30.
本文引用的文献
1
Improved utilization of ADAS-cog assessment data through item response theory based pharmacometric modeling.通过基于项目反应理论的药动学建模提高阿尔茨海默病协作组认知评估（ADAS-cog）数据的利用率。
Pharm Res. 2014 Aug;31(8):2152-65. doi: 10.1007/s11095-014-1315-5. Epub 2014 Mar 5.
2
A time to event tutorial for pharmacometricians.给药理计量学家的事件发生时间教程。
CPT Pharmacometrics Syst Pharmacol. 2013 May 15;2(5):e43. doi: 10.1038/psp.2013.18.
3
Disease progression and neuroscience.疾病进展与神经科学。
J Pharmacokinet Pharmacodyn. 2013 Jun;40(3):369-76. doi: 10.1007/s10928-013-9316-2. Epub 2013 Apr 17.
4
Combining patient-level and summary-level data for Alzheimer's disease modeling and simulation: a β regression meta-analysis.结合阿尔茨海默病建模和模拟的患者水平和汇总水平数据：β回归荟萃分析。
J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):479-98. doi: 10.1007/s10928-012-9263-3. Epub 2012 Jul 21.
5
Modeling helps in understanding antidepressants.建模有助于理解抗抑郁药。
Clin Pharmacol Ther. 2012 Aug;92(2):155-6. doi: 10.1038/clpt.2012.88.
6
Disease progress and response to treatment as predictors of survival, disability, cognitive impairment and depression in Parkinson's disease.疾病进展和治疗反应对帕金森病患者生存、残疾、认知障碍和抑郁的预测作用。
Br J Clin Pharmacol. 2012 Aug;74(2):284-95. doi: 10.1111/j.1365-2125.2012.04208.x.
7
Progression of motor and nonmotor features of Parkinson's disease and their response to treatment.帕金森病运动和非运动特征的进展及其对治疗的反应。
Br J Clin Pharmacol. 2012 Aug;74(2):267-83. doi: 10.1111/j.1365-2125.2012.04192.x.
8
An improved model for disease progression in patients from the Alzheimer's disease neuroimaging initiative.阿尔茨海默病神经影像学倡议患者疾病进展的改进模型。
J Clin Pharmacol. 2012 May;52(5):629-44. doi: 10.1177/0091270011405497. Epub 2011 Jun 9.
9
Interpreting the results of Parkinson's disease clinical trials: time for a change.解读帕金森病临床试验结果：是时候做出改变了。
Mov Disord. 2011 Mar;26(4):569-77. doi: 10.1002/mds.23555. Epub 2011 Mar 2.
10
Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.从临床角度解读群体药代动力学-药效学分析。
Br J Clin Pharmacol. 2011 Jun;71(6):807-14. doi: 10.1111/j.1365-2125.2010.03891.x.
Zotero 插件